Squarepoint
NAGE

Squarepoint’s Niagen Bioscience NAGE Stock Holding History

Squarepoint’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393K Buy
123,054
+30,711
+33% +$125K ﹤0.01% 3621
2026
Q1 		$407K Sell
92,343
-68,812
-43% -$372K ﹤0.01% 3468
2025
Q4 		$1.02M Buy
161,155
+116,472
+261% +$810K ﹤0.01% 2582
2025
Q3 		$417K Buy
+44,683
New +$451K ﹤0.01% 3402
2025
Q2 		– Sell
-59,070
Closed -$408K – 5216
2025
Q1 		$408K Sell
59,070
-45,564
-44% -$286K ﹤0.01% 3485
2024
Q4 		$555K Buy
+104,634
New +$573K ﹤0.01% 3637
2024
Q2 		– Sell
-36,461
Closed -$127K – 4767
2024
Q1 		$127K Sell
36,461
-25,438
-41% -$47.1K ﹤0.01% 3745
2023
Q4 		$88.5K Buy
61,899
+3,632
+6% +$5.06K ﹤0.01% 3772
2023
Q3 		$85.1K Buy
58,267
+19,191
+49% +$30K ﹤0.01% 3584
2023
Q2 		$61.3K Buy
39,076
+21,093
+117% +$31.5K ﹤0.01% 3426
2023
Q1 		$27.5K Buy
+17,983
New +$32K ﹤0.01% 3108
2022
Q3 		– Sell
-27,432
Closed -$46K – 3542
2022
Q2 		$46K Buy
+27,432
New +$53.6K ﹤0.01% 2714
2022
Q1 		– Sell
-13,947
Closed -$52K – 3650
2021
Q4 		$52K Buy
+13,947
New +$75.3K ﹤0.01% 3015
2021
Q3 		– Sell
-33,581
Closed -$331K – 3536
2021
Q2 		$331K Buy
33,581
+17,981
+115% +$157K ﹤0.01% 2457
2021
Q1 		$146K Sell
15,600
-13,877
-47% -$110K ﹤0.01% 2804
2020
Q4 		$141K Sell
29,477
-8,263
-22% -$40.3K ﹤0.01% 2632
2020
Q3 		$151K Buy
+37,740
New +$182K ﹤0.01% 2194
2018
Q2 		– Sell
-55,450
Closed -$233K – 2106
2018
Q1 		$233K Buy
+55,450
New +$290K ﹤0.01% 1431
2017
Q4 		– Sell
-30,000
Closed -$129K – 2385
2017
Q3 		$129K Buy
30,000
+6,639
+28% +$24.3K ﹤0.01% 1482
2017
Q2 		$89K Buy
+23,361
New +$74K ﹤0.01% 1418

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Squarepoint's NAGE Position: Q2 2026 in Review

Squarepoint increased its Niagen Bioscience (NAGE) stake by 33% in Q2 2026, buying an estimated $125K and bringing the position to 123,054 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #3621.

Squarepoint first reported a position in NAGE in Q2 2017 and has held it in 20 quarters since. The position peaked at $1.02M in Q4 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Squarepoint held 123,054 shares of Niagen Bioscience worth $393K as of Q2 2026.
  • Squarepoint bought 30,711 Niagen Bioscience shares in Q2 2026, an estimated $125K.
  • Niagen Bioscience made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3621 holding.
  • Squarepoint first reported a position in Niagen Bioscience in Q2 2017 and has held it in 20 quarters since.
  • Squarepoint's Niagen Bioscience position peaked at $1.02M in Q4 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.